RAdd image
Retatrutide
Weight LossSingleA triple agonist of GLP-1, GIP, and glucagon receptors in late-stage clinical trials. Phase 2 data showed ~24% body-weight loss at 48 weeks.
Half-life
144 h
Common dose
2 – 12 mg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Retatrutide combines GLP-1's satiety and insulin effects, GIP's adipose action, and glucagon's lipolysis and energy-expenditure boost. The triple-agonist approach drives both reduced intake and increased burn.
Protocol notes
Trial titration: 2 mg weekly with 2–4 mg increments every 4 weeks up to 12 mg weekly. Conservative titration is critical for GI tolerance.
Reported side effects
Nausea, vomiting, diarrhea, increased heart rate, transient blood-pressure effects, fatigue.